Survival Improves With Atezolizumab Switch Therapy in BRAF+ Melanoma
Long-term findings from the phase 2 ImmunoCobiVem trial show overall survival (OS) numerically improved among patients with BRAF V600–positive melanoma who switched early to atezolizumab following run-in treatment with vemurafenib plus cobimetinib. However, a relevant number experienced rapid progression after switching to immune checkpoint inhibition. Median OS was 40.2 months in the continuous targeted therapy group vs 49.6 months in the early switch group. Median PFS1 was 13.0 months vs 5.9 months, respectively.
Reference News
Long-term findings from the phase 2 ImmunoCobiVem trial show overall survival (OS) numerically improved among patients with BRAF V600–positive melanoma who switched early to atezolizumab following run-in treatment with vemurafenib plus cobimetinib. However, a relevant number experienced rapid progression after switching to immune checkpoint inhibition. Median OS was 40.2 months in the continuous targeted therapy group vs 49.6 months in the early switch group. Median PFS1 was 13.0 months vs 5.9 months, respectively.
Early switch to atezolizumab after vemurafenib plus cobimetinib in BRAF V600–positive melanoma showed a trend toward improved survival but lacked statistical significance. Median OS was 40.2 months in the continuous targeted therapy group vs 49.6 months in the switch group, with 60-month OS rates of 40% vs 45%. Rapid progression after early switch to ICI was observed in a relevant number of patients.